Published on 7 Mar 2024 on Zacks via Yahoo Finance
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
Investors are always looking for stocks that are poised to beat at earnings season and RAPT Therapeutics, Inc. RAPT may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because RAPT Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for RAPT in this report.In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 84 cents per share for RAPT, compared to a broader Zacks Consensus Estimate of a loss of 85 cents per share. This suggests that analysts have very recently bumped up their estimates for RAPT, giving the stock a Zacks Earnings ESP of +0.94% heading into earnings season.
Rapt Therapeutics Price and EPS Surprise
